Company profile
Noema Pharma AG
The biotech company develops drugs for the treatment of diseases of the central nervous system. It has a well-differentiated pipeline with four mid-clinical therapeutic candidates that have been licensed by Roche. Noema Pharma raised CHF 103 million in a series B financing round in the first quarter of 2023.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2024
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
